Have your say Australia

  • Home
  • Have your say Australia

Have your say Australia Have your say and vote your way on news and public opinion

Is Beef About to Be Declared a Drug?In a press conference that has left both nutritionists and cattle ranchers in a stat...
04/05/2026

Is Beef About to Be Declared a Drug?

In a press conference that has left both nutritionists and cattle ranchers in a state of existential whiplash, Health Secretary Robert F. Kennedy Jr. declared today that his strict carnivore regimen—essentially "gnawing on red meat"—has completely eliminated his atrial fibrillation and "melted away" dangerous visceral fat.

While followers of the "Make America Healthy Again" (MAHA) movement cheered, legal experts and regulatory watchdogs are pointing to a looming, steak-shaped crisis: by the FDA’s own rigid definitions, Secretary Kennedy may have just inadvertently turned the American cow into an unapproved new drug.

The ‘Intended Use’ Trap

According to longstanding FDA logic, a substance is classified as a drug the moment its manufacturer or distributor implies it can "cure, treat, or prevent a disease." Historically, the agency has used this rule to shut down everything from cherry farmers claiming antioxidants help gout to supplement companies touting the benefits of Vitamin C.

"The law doesn't care if it’s a pill or a Porterhouse," says the regulations. "If the head of the Department of Health and Human Services stands at a podium and says ‘Beef cured my heart condition,’ he is establishing an ‘intended use’ for beef as a medical treatment. Under the Federal Food, Drug, and Cosmetic Act, that makes the ribeye an unapproved drug."

The Cavadex Controversy: A Tale of Two Standards

The absurdity of the situation is highlighted by the agency's ongoing battle with Cavadex (cyclodextrin). Despite peer-reviewed papers and human case series suggesting the compound—a sugar-based ring used for decades as an FDA-approved excipient—can actually reverse arterial plaque, the FDA has cracked down on its sale.

Cyclodextrins are in all our food, cosmetics, medicines and is safer than beef.

The agency’s reasoning? Because Cavadex is marketed to treat heart disease, it must undergo the multi-billion-dollar drug approval process, regardless of its safety profile or efficacy.
“The double standard is almost too perfect,” says one industry insider. “One substance has solid preclinical data and published case series showing it reverses the world’s number one killer, and it’s treated like a biohazard. The other is a T-bone supported by a powerful personal anecdote, and suddenly the rules get… flexible.”
A Future of Prescription-Only Protein?

If the FDA intends to maintain its "sacred standards" of consistency, the American dinner plate is about to get a lot more bureaucratic. Analysts are already joking about a dystopian shift in food regulation:

Pharmacy-Grade Beef: High-marbling cuts available only behind the counter with a valid prescription from a cardiologist.

Black-Box Warnings: Hamburgers sporting labels that read: “CAUTION: Not FDA-approved to treat AFib or obesity. Side effects may include meat sweats and increased vitality.”

Import Bans: Federal agents seizing "contraband" grass-fed steaks from Australia that lack the necessary New Drug Application (NDA) paperwork.

The Rancher’s Dilemma

For now, the administration seems content to let the contradiction stand. But as Secretary Kennedy continues to promote "food as medicine," the FDA finds itself in a corner. If they don't regulate beef like a drug, they admit their standards for products like Cavadex are arbitrary. If they do regulate it, they effectively ban the American BBQ.

As the absurdity speaks for itself, Americans are left wondering if their next trip to the grocery store will soon require a co-pay and a trip to the medical clinic.
for more stories visit www.exposedmedicine.com

The Holy Grail of Cardiology Has ArrivedPRESS RELEASE • JAN 21, 2026 07:40 ESTPeer-Reviewed Paper Confirms Cavadex Drive...
22/01/2026

The Holy Grail of Cardiology Has Arrived
PRESS RELEASE • JAN 21, 2026 07:40 EST
Peer-Reviewed Paper Confirms Cavadex Drives Plummeting Coronary Artery Calcium Scores : Reversing the Irreversible

ROBINA AND QUEENSLAND, AUSTRALIA, January 21, 2026 (Newswire.com) - Today marks one of the most profound moments in the history of cardiovascular medicine.
A newly published, peer-reviewed multi-center retrospective case series has delivered irrefutable evidence that high-viscosity 2-Hydroxypropyl-β-cyclodextrin (Cavadex) can reverse established coronary artery calcification, a biological outcome long considered impossible.
Published Paper:
Longitudinal Retrospective Analysis of High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex) in the Regression of Atherosclerotic Cardiovascular Disease: A Multi-Center Observational Case Series
Authors: Kyle Hodgetts (Cholrem Pty Ltd), James Roberts, MD
Journal: Cardiology Research and Cardiovascular Medicine (Gavin Publishers)
https://www.gavinpublishers.com/article/view/regression-of-atherosclerotic-plaque-via-highviscosity-2hydroxypropylcyclodextrin-cavadex-a-multicenter-retrospective-case-series
For more than 30 years, the cardiology world has operated under an unbreakable rule:
Once coronary artery calcium (CAC) appears on a CT scan, it never goes down.
It only increases - year after year, relentlessly - at typical annualized rates of 14-25% (often 20-30% in high-risk patients). Spontaneous, clinically significant regression is virtually unheard of in the scientific literature. Even the most powerful lipid-lowering drugs - high-intensity statins, PCSK9 inhibitors, ezetimibe combinations - do not reverse CAC scores. At best, they slow the rise; at worst, they accelerate densification and push scores higher.
That era is over.
In this real-world evidence cohort, patients using the proprietary high-viscosity re**al formulation of Cavadex achieved dramatic, objective plummeting of CAC scores:
• Absolute reductions of up to **320 points** within approximately 12 months
• One patient reversed a consistent **+27-28% annual progression** to **-10.5% regression** - a nearly 40-percentage-point swing in disease trajectory
• Net regression magnitudes that dwarf expected progression (e.g., -865 units versus a projected +545-unit increase)
• Rapid structural reversal in select cases, including a **70-point drop** in just **9 weeks**
These are not subtle statistical blips. These are biological reversals of calcified plaque burden, the very hallmark of advanced atherosclerosis long thought to be permanent scar tissue.
"This is the holy grail we have been searching for," said lead author Kyle Hodgetts. "We are no longer talking about slowing disease or stabilizing vulnerable plaques. We are witnessing rapid active removal of decades of accumulated calcification, something no therapy in the history of cardiology has reliably achieved."
Why This Changes CVD Treatment Forever
Coronary artery calcium is the single most powerful non-invasive predictor of heart attack, stroke, and cardiovascular death. A therapy capable of driving CAC scores downward fundamentally alters the treatment landscape:
• For the first time, "end-stage" patients with refractory angina, diffuse multivessel disease unsuitable for stenting or bypass, or statin intolerance may have a real disease-modifying option.
• The potential to prevent millions of major adverse cardiovascular events worldwide, extending healthy lifespans and slashing the global burden of the planet's #1 killer (over 19 million deaths annually).
• A shift from the decades-old paradigm of "manage progression" to the new reality of "reverse the disease."
The mechanism: direct solubilization of sub-endothelial cholesterol crystals, deactivation of NLRP3-driven inflammation, and enhanced cholesterol efflux from plaque macrophages - aligns perfectly with the observed CAC regression and offers a completely novel pathway beyond LDL-receptor modulation.
The published data is consistent and profound.
Cardiology textbooks will need to be rewritten. The wait for a true reversal therapy in atherosclerosis is over.
Media & Professional Inquiries:
Kyle Hodgetts
Cholrem Pty Ltd
Email: [email protected]

By Kyle Hodgetts · 2026 · Read by 1175 — Regression of Atherosclerotic Plaque Via High-Viscosity 2-Hydroxypropyl-Β-Cyclodextrin (Cavadex): A Multi-Center Retrospective Case Series in Cardiology Research and Cardiovascular Medicine

Address


Alerts

Be the first to know and let us send you an email when Have your say Australia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Have your say Australia:

Shortcuts

  • Want your business to be the top-listed media company?

Share